The FDA is not "awaiting" PDD data, just the company is. The company will then use it to design the P2/3. That will be submitted to the FDA when it's ready.
And whether it is the old controlled trial data or new OLE data, we don't know. There's a good deal of endpoint data that has not been released, so it's not clear.